Educated CD14+ Cells for Inflammation Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for acute radiation syndrome (ARS) and other inflammatory conditions are limited by the complexity and toxicity of allogeneic bone marrow transplants and the lack of effective adjunct therapies, with existing cell-based therapies showing inconsistent efficacy and complications.

Innovation Solution

The development of educated CD14+ cells and extracellular vesicles (EVs) from mesenchymal stromal cells (MSCs) exposed to synthetic lipid A aminoalkyl glucosaminide phosphate (AGP) molecules, which are co-cultured with CD14+ cells to induce an anti-inflammatory phenotype, providing a therapeutically effective cell population for treating inflammatory diseases and injuries.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If allogeneic bone marrow transplant is used to treat ARS, then patient survival can be improved, but treatment complexity and toxicity increase

Engineering Contradiction:

Improvepatient survivalVSAvoidtreatment complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent extracts the essential therapeutic function from complex allogeneic BMT by isolating and utilizing specific cell types (macrophages, monocytes) and their mediators (exosomes, cytokines) that provide anti-inflammatory and tissue repair effects, eliminating the need for complete bone marrow transplantation

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The treatment is segmented into modular components including educated macrophages, exosomes, and cytokine combinations that can be administered separately and work synergistically, allowing flexible dosing and reduced procedural complexity compared to whole BMT

Inventive Principle:

Principle #1Segmentation

2Reliability

If allogeneic bone marrow transplant is used to treat ARS, then patient survival can be improved, but treatment time is extended

Engineering Contradiction:

Improvepatient survivalVSAvoidtreatment time

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

Macrophages and exosomes are pre-generated and characterized in controlled laboratory conditions before administration to the patient, ensuring therapeutic readiness and eliminating time-consuming in-clinic processing steps required for allogeneic BMT donor identification and preparation

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The therapy utilizes the patient's own immune system components (autologous macrophages and exosomes) that are stimulated and educated in vitro, eliminating the need to wait for a compatible donor and reducing overall treatment timeline

Inventive Principle:

Principle #25Self-service

3Productivity

If colony-stimulating factors are administered to treat ARS, then hematopoietic recovery is promoted, but harmful effects on patient cells increase

Engineering Contradiction:

Improvehematopoietic recoveryVSAvoidtoxicity

Core Design Contradiction:

ProductivityVSObject-generated harmful factors

Solution Approach 1:

The patent introduces educated macrophages and exosomes as intermediary therapeutic agents that mediate tissue repair and immune modulation through paracrine signaling, replacing direct cytotoxic effects of colony-stimulating factors with beneficial anti-inflammatory and regenerative actions

Inventive Principle:

Principle #24Intermediary (Mediator)

4Productivity

If cell-based therapies are used to treat ARS, then tissue repair can be accelerated, but efficacy consistency and safety are reduced

Engineering Contradiction:

Improvetissue repair rateVSAvoidtherapy efficacy consistency

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The therapy optimizes critical parameters including macrophage differentiation stage, exosome size distribution (30-200 nm), cytokine concentration ratios, and administration timing to ensure consistent and reproducible therapeutic effects across different patients and treatment batches

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The approach effectively generates anti-inflammatory macrophages or monocytes that can be administered to treat ARS and other inflammatory conditions, enhancing survival and reducing clinical side effects by promoting tissue repair and immune modulation.

Implementation Method 1

The disclosure relates to the use of Toll-Like Receptor 4 agonists to treat inflammation and tissue injury

Methodology Applied

Scientific EffectToll-Like Receptor 4 activation:

Implementation Method 2

extracellular vesicles (EVs) from mesenchymal stromal cells (MSCs) stimulated with CRX molecules

Methodology Applied

Scientific EffectExtracellular vesicle transport:

Data Source

PatentUS20240287462A1Use of Toll-Like Receptor 4 Agonists to Treat Inflammation and Tissue Injury

Publication Date: 2024.08.29 WISCONSIN ALUMNI RES FOUND

AI summary

The disclosure relates to populations of educated macrophages and monocytes generated ex vivo or in vivo, and methods of making and using the same using lipid A aminoalkyl glucosaminide phosphate molecules, such as CRX molecules or extracellular vesicles (EVs) from mesenchymal stromal cells (MSC) stimulated with CRX molecules. Also described are EVs and methods for making and using the same from MSCs exposed to CRX.